LTV-1 is a potent lymphoid tyrosine phosphatase (LYP) inhibitor (antagonist) with IC50 of 508 nM for LYP inhibition in T cells. LTV-1 may be used to be utilized in study/research of autoimmune-related diseases.

Physicochemical Properties

Molecular Formula	C26H20N2O5S
Molecular Weight	472.5124
Exact Mass	472.109
CAS #	347379-29-7
PubChem CID	1920999
Appearance	Yellow to brown solid powder
Density	1.5±0.1 g/cm3
Index of Refraction	1.723
LogP	4.99
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	6
Heavy Atom Count	34
Complexity	835
Defined Atom Stereocenter Count	0
SMILES	CC1=CC=CC=C1N2C(=O)/C(=C/C3=CC=C(C=C3)OCC4=CC(=CC=C4)C(=O)O)/C(=O)NC2=S
InChi Key	DSYDHTCEVHUCPE-KGENOOAVSA-N
InChi Code	InChI=1S/C26H20N2O5S/c1-16-5-2-3-8-22(16)28-24(30)21(23(29)27-26(28)34)14-17-9-11-20(12-10-17)33-15-18-6-4-7-19(13-18)25(31)32/h2-14H,15H2,1H3,(H,31,32)(H,27,29,34)/b21-14+
Chemical Name	3-[[4-[(E)-[1-(2-methylphenyl)-4,6-dioxo-2-sulfanylidene-1,3-diazinan-5-ylidene]methyl]phenoxy]methyl]benzoic acid
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	Even at the highest tested concentration of 40 μM, LTV-1 (1.25-40 μM) did not significantly affect cell viability as measured by the metabolic rate assay. Consequently, HeLa cells, Jurkat TAg T cells, and peripheral blood mononuclear cells (PBMC) do not respond negatively to LTV-1 [1].
Cell Assay	Cell Viability Assay[1] Cell Types: HeLa cells, Jurkat TAg T cells and PBMC Tested Concentrations: 1.25, 2.5, 5.0, 10, 20 and 40 μM Incubation Duration: 48 hrs (hours) Experimental Results: No significant effect on cell viability (metabolism) rate assay), even at the highest concentration tested (40 μM).
References	[1]. LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol. 2012 Mar 18;8(5):437-446.

Solubility Data

Solubility (In Vitro)

DMSO : ~22.73 mg/mL (~48.10 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (5.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (4.40 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.1164 mL	10.5818 mL	21.1636 mL
	5 mM	0.4233 mL	2.1164 mL	4.2327 mL
	10 mM	0.2116 mL	1.0582 mL	2.1164 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.